Company Filing History:

7 out of 417

Astellas Pharma Gmbh

patents

4 out of 329

Yamanouchi Pharmaceutical Company Ltd.

Years Active: 2002-2019

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10508084 - Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and intermediate used in the method (2019-12-17),

2. 9951022 - Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and intermediate used in the method (2018-04-24),

3. 9598373 - Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and intermediate used in the method (2017-03-21),

4. RE43481 - Diazepan derivatives or salts thereof (2012-06-18),

5. 7982049 - α-form or β-form crystal of acetanilide derivative (2011-07-19),

6. 7342117 - α-form or β-form crystal of acetanilide derivative (2008-03-11),

7. 7307074 - Diazepan derivatives or salts thereof (2007-12-11),

8. 7285554 - Pyrazole derivative (2007-10-23),

9. 7247635 - Pyrazole derivative (2007-07-24),

10. 6958339 - Pyrazole derivative (2005-10-25),

11. 6797706 - Heterocyclecarboxamide derivative (2004-09-28),

12. 6642224 - Diazepan derivatives or salts thereof (2003-11-04),

13. 6432963 - Pyrimidine-5-carboxamide derivatives (2002-08-13),

14. 6348480 - Pharmaceutical compound comprising a pyrazole derivative and methods of using the same for the treatment of calcium release-activated calcium channel associated diseases (2002-02-19),

Title: The Innovative Mind of Souichirou Kawazoe

Introduction

Souichirou Kawazoe is a prominent inventor based in Ibaraki, Japan, known for his significant contributions to pharmaceutical technologies. With a remarkable portfolio of 14 patents, Kawazoe has played a pivotal role in developing innovative methods for producing compounds with therapeutic potential.

Latest Patents

One of Kawazoe's latest patents is a groundbreaking method for producing a 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound. This compound exhibits superior agonistic activity at the arginine vasopressin V2 receptor, making it a valuable active ingredient for pharmaceutical compositions aimed at treating various medical conditions, including urinary frequency, urinary incontinence, enuresis, central diabetes insipidus, nocturia, and nocturnal enuresis. The innovative production method is advantageous for industrial applications due to its reduced steps, higher yield, and lower cost compared to existing methods in the field.

Career Highlights

Kawazoe has had a distinguished career in the pharmaceutical industry, contributing his expertise to leading companies such as Astellas Pharma GmbH and Yamanouchi Pharmaceutical Company Ltd. His work has significantly impacted the development of new and effective therapeutics, showcasing his dedication to improving patient care through innovative chemistry.

Collaborations

Throughout his career, Kawazoe has collaborated with notable professionals in the field, including Makoto Takeuchi and Keizo Sugasawa. These collaborations have fostered creativity and advancement in research, enabling the development of new technologies and methodologies.

Conclusion

Souichirou Kawazoe’s contributions to the field of pharmaceutical chemistry underscore his status as an influential inventor. His recent patents highlight his commitment to advancing medical science and improving treatment options for patients around the world. With a solid track record of innovation, Kawazoe's future endeavors are eagerly anticipated by the industry.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

1 patent (CIPO):

Please report any incorrect information to support@idiyas.com

1 patent (EPO):

Please report any incorrect information to support@idiyas.com

1 patent pending (EPO):

Please report any incorrect information to support@idiyas.com